Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X:
“New study alert!
GLP-1 receptor agonists (used for diabetes/obesity) linked to lower progression rates from MGUS → SMM and SMM → MM.
GLP-1 users showed significantly reduced progression vs non-users.
More trials and mechanistic research needed!“
Title: Glp-1 receptor agonist use is associated with lower risk of progression from MGUS to SMM or MM in a large real-world cohort
Authors: Arooj Abidi, Hashim Mann, Sneha Purvey, Bharadhwaj Kolipakkam, Brian Cassel, Victor Yazbeck
You can read the full article in ASH Blood.
More posts featuring Al-Ola A Abdallah.
